Get the latest crypto news, updates, and reports by subscribing to our free newsletter.
Giấy phép số 4978/GP-TTĐT do Sở Thông tin và Truyền thông Hà Nội cấp ngày 14 tháng 10 năm 2019 / Giấy phép SĐ, BS GP ICP số 2107/GP-TTĐT do Sở TTTT Hà Nội cấp ngày 13/7/2022.
© 2026 Index.vn
At Build to Last 2026, Saint-Gobain Vietnam announced it has achieved “Zero Carbon” manufacturing for its DURAflex fiber cement sheet plant in Quảng Trị, with no carbon emissions for Scope 1 and Scope 2. The company said it is the first in its industry to reach this milestone. The Zero…
The Gross Law Firm has issued a notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX) regarding a potential class action and the possibility of appointment as lead plaintiff. Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm about possible lead plaintiff appointment. Appointment as lead plaintiff is not required to participate in any recovery.
Class period: February 9, 2022 to January 27, 2026.
Allegations: The complaint states that defendants provided investors with information about REGENXBIO’s plan to develop and commercialize RGX-111, a one-time gene therapy intended to treat severe Mucopolysaccharidosis Type I (Hurler syndrome).
The complaint alleges that defendants’ statements included positive assertions about RGX-111’s future trial success, citing continuing positive biomarker and safety data from an ongoing Phase I/II study. It further alleges that these statements were made while defendants disseminated false and misleading statements and/or concealed material adverse facts related to the efficacy and safety of RGX-111.
On January 28, 2026, the U.S. Food and Drug Administration placed a clinical hold on RGX-111. The complaint states that REGENXBIO announced an intraventricular CNS tumor was found in a participant treated in the RGX-111 Phase I/II study.
Following the announcement, REGENXBIO’s stock declined from a closing price of $13.41 on January 27, 2026 to $11.01 on January 28, 2026, representing a 17.8% single-day drop.
Deadline: April 14, 2026.
The firm states that shareholders should not delay in registering for the class action. After registering as a shareholder who purchased shares of RGNX during the listed timeframe, shareholders will be enrolled in a portfolio monitoring software program to provide status updates throughout the case lifecycle.
The deadline to seek to be a lead plaintiff is also April 14, 2026. The firm states there is no cost or obligation to participate.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Attorney advertising. Prior results do not guarantee similar outcomes.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
